Patents by Inventor SANTOSH S. KULKARNI

SANTOSH S. KULKARNI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFOXIMINE GLYCOSIDASE INHIBITORS
    Publication number: 20250115604
    Abstract: Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: October 11, 2024
    Publication date: April 10, 2025
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20250100983
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: September 25, 2024
    Publication date: March 27, 2025
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 12202809
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: January 21, 2025
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20250019353
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: July 2, 2024
    Publication date: January 16, 2025
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Succinate and fumarate acid addition salts of piperazine derivatives
    Patent number: 12195455
    Abstract: The invention relates to succinic acid addition salts or fumaric acid addition salts of piperazine derivatives of formula (I), as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: January 14, 2025
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Robert Hett, David Malcolm Crowe
  • Benzothiadiazepine compounds and their use as bile acid modulators
    Patent number: 12187690
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 7, 2025
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Jan Mattsson, Ingemar Starke, Santosh S. Kulkarni
  • Glycosidase inhibitors
    Patent number: 12187741
    Abstract: The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 7, 2025
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • INHIBITORS OF THE MENIN-MLL INTERACTION
    Publication number: 20240400564
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 5, 2024
    Inventors: Salvacion CACATIAN, Santosh S. KULKARNI, Swapan Kumar SAMANTA, Virsinha Venkat REDDY, Gerard M. MCGEEHAN, William H. MILLER, Nicholas Paul CAMP
  • Sulfoximine glycosidase inhibitors
    Patent number: 12157734
    Abstract: Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: December 3, 2024
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 12134606
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 12, 2023
    Date of Patent: November 5, 2024
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 12060338
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: August 13, 2024
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Benzothiazepine compounds and their use as bile acid modulators
    Patent number: 12024495
    Abstract: The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: July 2, 2024
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Pyrrolidine glycosidase inhibitors
    Patent number: 12016852
    Abstract: Compounds of formula (I) wherein A, W, R3b, Z and p have the meaning according to the claims, can be employed, inter alia, for the treatment of taupathies and Alzheimer's disease.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: June 25, 2024
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Grant Wishart, Santosh S. Kulkarni, Paul Rakesh
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20240109854
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: June 2, 2023
    Publication date: April 4, 2024
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • SARS-COV-2 MPRO INHIBITOR COMPOUNDS
    Publication number: 20240083845
    Abstract: The disclosures herein relate to compounds of Formula (1?): or a salt thereof, wherein A, Q, X, Z, L, R2, R3 and R9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Miles Stuart CONGREVE, John Andrew CHRISTOPHER, Mark PICKWORTH, Chris DE GRAAF, Alicia Perez HIGUERUELO, Jonathan Stephen MASON, Santosh S. KULKARNI
  • Inhibitors of the menin-MLL interaction
    Patent number: 11919901
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: March 5, 2024
    Assignees: Syndax Pharmaceuticals, Inc., Vitae Pharmaceuticals, LLC
    Inventors: Gerard M. McGeehan, William H. Miller, Nicholas Paul Camp, Salvacion Cacatian, Santosh S. Kulkarni, Swapan Kumar Samanta, Virsinha Venkat Reddy
  • BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20240067617
    Abstract: The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: July 5, 2023
    Publication date: February 29, 2024
    Inventors: Ingemar Starke, Per-Göran Gillberg, Santosh S. Kulkarni, Ellen Strängberg
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11891368
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: February 6, 2024
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
    Publication number: 20230406832
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: February 3, 2023
    Publication date: December 21, 2023
    Inventors: Per-Göran Gillberg, Jan Mattsson, Ingemar Starke, Santosh S. Kulkarni
  • Tetrahydro-benzoazepine glycosidase inhibitors
    Patent number: 11795165
    Abstract: Compounds of formula (I?), wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R??, m and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: October 24, 2023
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Grant Wishart, Paul Rakesh